Premium
THE GENE EXPRESSION PROFILE AND TETRASPANIN PROTEIN CO029 ON THE HUMAN COLORRETAL CANCER LATERALITY
Author(s) -
Braga Lucélia Antunes,
Assis Jéssica Vieira,
Moraes Vanessa Silva,
Silva Istéfani Dayse,
Grenfell Rafaella Fortini
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.811.11
Subject(s) - tetraspanin , colorectal cancer , immunohistochemistry , biology , metastasis , cancer , cancer research , gene expression , gene , pathology , cell , medicine , immunology , genetics
Colorectal cancer (CRC) is one of the most prevalent neoplasms and presents a multifactorial and complex etiopathogenesis, not yet fully elucidated. Studies have shown that tumors of the right colon differ significantly from neoplasms of the left colon, because they present greater risks of metastasis, are less responsive and exhibit different predictive and prognostic markers. Some of these markers have been studied, such as the tetraspanin CO029 protein, which favors cell motility, and epithelial‐mesenchymal (EMT) and neoplastic stem cell (CSC) markers, which are associated with loss of cell differentiation. According to studies, the three markers cited are closely associated with tumor progression. It has already been observed that in RCC tumor cells these markers present a high expression. Therefore, the analysis of the expression profile of tetraspanin CO029 and other markers in the RCC may become potential predictive tools for this neoplasia. Thus, the objective of the study is to evaluate the gene and protein expression of tetraspanin CO029 and correlate with laterality of RCC and with EMT and CSC markers. Therefore, it is proposed the use of human samples affected by the neoplasia proposed in different histopathological stages, for the evaluation of the immunohistochemical expression of tetraspanin CO029 protein. In addition, we will evaluate the gene expression of the three mentioned markers through the extraction of messenger RNA (mRNA) from these samples, for quantitative PCR (qRT‐PCR). The clinical data of the patients will be used for correlation with the expression of the proposed markers. Currently our efforts are concentrated in the evaluation by qRT‐PCR of the samples affected by CCR, where we observed that the samples located in the right colon presents a greater expression of tetraspanin CO029, corroborating with works that associate this protein with intensification of metastasis, due to the function of give motility to the cell. We are jointly conducting the production of anti‐tetraspanin CO029 monoclonal antibodies by in vitro methodology, which will be used for immunohistochemical labeling and in future projects, tested as monoclonal therapy. The production is in the phase of selection of positive hybridomas. Considering that the number of RCC cases is increasing in Brazil and in the world, it is important to carry out studies to elucidate this neoplasia. This project is relevant when we refer to possible predictive markers and future therapeutic targets, as it may make treatment personalized and possibly more efficient. Financial support: Fiocruz, CNPq, FIOCÂNCER IRR. Support or Funding Information Financial support: Fiocruz, CNPq, FIOCÂNCER IRR. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .